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CYP2D Microsatellite Polymorphism in Lewy Body Variant
of  Alzheimer’s Disease and Parkinson's Disease
The Lewy body variant (LBV) has been recognized as a distinct subset of Alzheimer’s disease (AD).  In
this study, we conducted an allelic association study in patients with pure AD, LBV and also Parkinson’s
disease (PD) by using the CYP2D microsatellite, the (dG-dT)n dinucleotide repeat (n = 16 - 27) located
between CYP2D8P and CYP2D7 genes.  The alleles longer than 21 repeat (the long-type alleles) were
excessively represented in LBV (allele frequency, 0.313) compared with the age-matched control (0.186)
(odds ratio = 1.99, p = 0.019 by χ2 test).  This overrepresentation was also found in PD (0.298) (odds ratio
= 1.86, p = 0.037), but not in pure AD (0.196).  The long-type alleles showed a strong association with the
CYP2D6 B mutation (odds ratio = 88.50, p < 0.001 by Fisher’s exact test), but not with the D mutation or
the deletion of CYP2D6 gene.  These findings confirmed a close association of the CYP2D locus with
LBV and PD, indicating the following two possibilities: the involvement of the CYP2D6 B mutation in
pathogenesis of LBV and PD in a dominant-negative manner; or the linkage disequilibrium of the CYP2D
microsatellite to another pathogenic gene locus.  The microsatellite of the CYP2D locus could be an
informative marker in the genetic study of LBV as well as PD.
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This laboratory was founded in 1994 with the aim of linking (bio)chemical research and clinical medicine. Thus, the scope of
our research encompasses the structure, function and regulation of various biomolecules, the pathophysiological significance
of bioreactions in relation to human diseases, and the application of molecular techniques to clinical diagnosis and therapy.
Our current interest is focused on poly(ADP-ribosyl)ation, nuclear (de)localization of proteins in association with apoptosis,










   Alzheimer’s disease (AD) and Parkinson’s disease (PD) are
considered complex multifactorial diseases, with an interaction
of genetic susceptibility [1, 2] and environmental factors against
a background of aging. The Lewy body variant (LBV) repre-
sents a clinico-pathologically defined subset of AD. It is char-
acterized by the presence of Lewy bodies (LBs) in neocortical
and subcortical regions of the AD brain. The LB is an intracyto-
plasmic neuronal inclusion and a hallmark of idiopathic PD.
Genetic analyses have revealed the association of the CYP2D6
B mutation with PD. CYP2D6 codes for one form of cytochrome
P450 enzyme, which is responsible for hydroxylation of several
substances.  The CYP2D gene cluster consists of CYP2D8P,
CYP2D7 and CYP2D6 genes in the order from 5' to 3' on chro-
mosome 22 at q13.1-13.2. The B mutation of the CYP2D6 gene
is a G to A transition at the intron 3 - exon 4 junction, which
shifts the position of the 3' splice site, leading to a frameshift.
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and inactivation of this enzyme.
      In the CYP2D gene locus, the microsatellite, a (dG-dT)n
dinucleotide repeat, is located between the CYP2D8P and
CYP2D7 genes.  In this allelic association study, we analyzed
the CYP2D microsatellite in patients with pure AD, LBV and
PD [3].  This microsatellite, which is in the linkage disequilib-
rium with the CYP2D6 B mutation, proved to be a useful marker
for assessment of CYP2D6 gene involvement in LB-associated
diseases (LBV and PD).
I. Polymorphism of the CYP2D microsatellite.
We found 12 alleles in the CYP2D microsatellite.  The size of
PCR products ranged from 96 to 118 bp (Figure 1). The number
of (dG-dT)n repeat ranged from 16 to 27.  We named each allele
A16 to A27 by the repeat number.
II. CYP2D microsatellite polymorphisms in pure AD, LBV and
PD.
We then analyzed the distribution of allele frequencies of CYP2D
microsatellites in the control and disease groups. The frequen-
cies of the short- and long-type alleles were significantly asso-
ciated with the control and disease groups.  The long-type allele
was excessively represented in LBV (0.313) compared with
control (0.186) or pure AD (0.196). The PD patients also showed
this overrepresentation (0.298).
III. CYP2D microsatellite polymorphisms and CYP2D6 B mu-
tation.
The allele frequencies of CYP2D microsatellites were associ-
ated with the CYP2D6 B mutation.  Its frequency was signifi-
cantly higher in LBV (0.281) than in control (0.157) or pure AD
(0.175)  The PD patients also showed a higher value (0.234),
although the difference did not reach a significant level in this
study.
IV. CYP2D microsatellite polymorphisms and CYP2D6 D mu-
tation.
We analyzed XbaI RFLP in order to investigate a relationship
between the structure of the CYP2D gene cluster and CYP2D
microsatellite genotypes.  Four haplotypes of XbaI RFLP were
identified by Southern blot analysis. The 11.5-kb haplotype, or
the D mutant allele (deletion mutation), was not associated with
the long-type allele.  The results of the XbaI RFLP study, com-
bined with those of the PCR analysis, indicated no
overrepresentation of the CYP2D6 D mutaion in any disease
groups.
These findings confirmed a close association of the CYP2D lo-
cus with LBV and PD, indicating the following two possibili-
ties: the involvement of the CYP2D6 B mutation in pathogen-
esis of LBV and PD in a dominant-negative manner; or the link-
age disequilibrium of the CYP2D microsatellite to another patho-
genic gene locus.  The microsatellite of the CYP2D locus could
be an informative marker in the genetic study of LBV as well as
PD.
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Figure 1.  Autoradiogram of the CYP2D microsatellites.  Geno-
types are shown under respective lanes.  The CYP2D
microsatellite alleles were categorized into two groups; the short-
type (A16 - A20) (S) and the long-type (A21 - A27) (L).  The
size of the A18 band was 100 bp.  “Ghost” bands appeared, at 2-
bp intervals, above and below the true band.
